[1]王佳玉,王臻,牛晓辉,等.肢体软组织肉瘤临床诊疗专家共识[J].临床肿瘤学杂志,2014,19(7):633-636.
[2]黄媛,陆维祺,周宇红.脂肪肉瘤及其治疗[J].国际肿瘤学杂志,2013,40(4):294-297.
[3]黄晓辉,李沛雨,赵旭东,等.原发性腹膜后脂肪肉瘤治疗策略[J].中国实用外科杂志,2013,33(2):156-158.
[4]林翠君,李丽红,黄春榆,等.脂肪肉瘤的CT、MRI表现与病理学对照[J].中国CT和MRI杂志,2015,13(8):108-111.
[5]Wan L,Tu C,Qi L,et al.Survivorship and prognostic factors for pleomorphic liposarcoma:A population-based study[J].J Orthop Surg Res,2021,16(1):1-10.
[6]杜丹阳,郭艳英.脂肪肉瘤的靶向治疗研究进展[J]癌症进展,2021,19(22):2275-2278.
[7]朱芸,周晓军.CDK4和MDM2在脂肪肉瘤诊断中的价值[J].诊断病理学杂志,2012,19(1):65-67.
[8]Abdul Razak AR,Bauer S,Suarez C,et al.Co-targeting of MDM2 and CDK4/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma:Results from a Proof-of-Concept,phase Ib study[J].Clin Cancer Res,2022,28(6):1087-1097.
[9]Kammerer-Jacquet SF,Thierry S,Cabillic F,et al.Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma:utility of p16 in combination with MDM2 and CDK4 immunohistochemistry[J].Hum Pathol,2017(59):34-40.
[10]Gahvari Z,Parkes A.Dedifferentiated liposarcoma:Systemic therapy options[J].Current Treatment Options in Oncology,2020,21(2):1-14.
[11]Schffski P.Established and experimental systemic treatment options for advanced liposarcoma[J].Oncology Research and Treatment,2022,45(9):525-543.
[12]Stacchiotti S,Van der Graaf WTA,Sanfilippo RG,et al.First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma:An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis[J].Cancer,2022,128(15):2932-2938.〖JP〗
[13]李蕊,左立杰,刘维丽,等.成人脂肪肉瘤临床化疗疗效分析[J].中国肿瘤临床与康复,2021,28(2):173-176.
[14]王雪,于胜吉.脂肪肉瘤的研究进展[J].癌症进展,2022,20(22):2269-2271.
[15]Tanriverdi O,Yildiz A.Current molecular and therapeutic advances in liposarcoma,rhabdomyosarcoma,leiomyosarcoma,synovial sarcoma,and angiosarcoma[J].J Oncol Pharm Pract,2022,28(3):635-645.